1. Home
  2. LGND
  3. LGND News

Latest Ligand Pharmaceuticals Incorporated (LGND) News on February 22, 2025

LGND

Argus Research

4 days ago

LGND: Raising target price to $126.00

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
LGND

Business Wire

9 days ago

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
LGND

Business Wire

16 days ago

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

LGND

Argus Research

18 days ago

LGND: Lowering target price to $123.00

LGND

Argus Research

25 days ago

LGND: Raising target price to $124.00

LGND

Argus Research

a month ago

LGND: Raising target price to $123.00

LGND

Argus Research

a month ago

LGND: Lowering target price to $114.00

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025
LGND

Zacks Small Cap Research

a month ago

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year
LGND

Simply Wall St.

2 months ago

Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year

LGND

Argus Research

2 months ago

LGND: Lowering target price to $119.00

LGND

Argus Research

2 months ago

LGND: Raising target price to $126.00

LGND: 2025 View Calls for 17% Topline Growth
LGND

Zacks Small Cap Research

2 months ago

LGND: 2025 View Calls for 17% Topline Growth

Ligand price target raised to $151 from $135 at Oppenheimer
LGND

TipRanks

2 months ago

Ligand price target raised to $151 from $135 at Oppenheimer

LGND

MT Newswires

2 months ago

Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $151 From $135, Maintains Outperform Rating

LGND

MT Newswires

2 months ago

RBC Raises Price Target on Ligand Pharmaceuticals to $143 From $141, Keeps Outperform Rating

LGND

Argus Research

2 months ago

LGND: Lowering target price to $125.00

LGND

MT Newswires

2 months ago

Ligand Pharmaceuticals Issues 2025 Guidance; 2024 Forecast Reaffirmed

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
LGND

Business Wire

2 months ago

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

LGND

Argus Research

3 months ago

LGND: Lowering target price to $126.00

LGND

MT Newswires

3 months ago

RBC Lifts Price Target on Ligand Pharmaceuticals to $141 From $140, Keeps Outperform Rating

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings
LGND

Simply Wall St.

3 months ago

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Ligand to Present at Stifel 2024 Healthcare Conference
LGND

Business Wire

3 months ago

Ligand to Present at Stifel 2024 Healthcare Conference

LGND

Argus Research

3 months ago

LGND: Raising target price to $127.00

LGND: 3Q Sales Surprise to the Upside
LGND

Zacks Small Cap Research

3 months ago

LGND: 3Q Sales Surprise to the Upside

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
LGND

Simply Wall St.

3 months ago

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price
LGND

Simply Wall St.

3 months ago

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price

Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
LGND

GuruFocus.com

3 months ago

Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

LGND

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

LGND

MT Newswires

3 months ago

Ligand Shares Rise After Q3 Tops Expectations, Guidance Raised

LGND

Associated Press Finance

3 months ago

Ligand: Q3 Earnings Snapshot

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
LGND

Business Wire

3 months ago

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need To Know Ahead Of Earnings
LGND

GuruFocus.com

4 months ago

Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need To Know Ahead Of Earnings

LGND

Argus Research

4 months ago

LGND: Lowering target price to $117.00

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
LGND

Business Wire

4 months ago

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
LGND

Business Wire

4 months ago

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
LGND

GlobeNewswire

4 months ago

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
LGND

GuruFocus.com

4 months ago

Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

LGND: Initiating Coverage – A Prince Among Royalty
LGND

Zacks Small Cap Research

4 months ago

LGND: Initiating Coverage – A Prince Among Royalty

LGND

Argus Research

4 months ago

LGND: Raising target price to $108.00

LGND

MT Newswires

5 months ago

Oppenheimer Initiates Ligand Pharmaceuticals at Outperform With $135 Price Target

Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?
LGND

Simply Wall St.

5 months ago

Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
LGND

Business Wire

6 months ago

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

LGND

Argus Research

6 months ago

LGND: Raising target price to $112.00

Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...
LGND

GuruFocus.com

6 months ago

Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...

LGND

Argus Research

6 months ago

LGND: Raising target price to $110.00

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
LGND

Business Wire

6 months ago

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings
LGND

Simply Wall St.

6 months ago

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Private Capital's Strategic Moves Highlight Ligand Pharmaceuticals in Q2 2024
LGND

GuruFocus.com

6 months ago

Private Capital's Strategic Moves Highlight Ligand Pharmaceuticals in Q2 2024

LGND

MT Newswires

6 months ago

Ligand Pharmaceuticals Insider Sold Shares Worth $1,797,133, According to a Recent SEC Filing

Insider Buying: CEO Todd Davis Acquires Shares of Ligand Pharmaceuticals Inc (LGND)
LGND

GuruFocus.com

6 months ago

Insider Buying: CEO Todd Davis Acquires Shares of Ligand Pharmaceuticals Inc (LGND)

Ligand Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
LGND

Simply Wall St.

6 months ago

Ligand Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

LGND

MT Newswires

6 months ago

Ligand Pharmaceuticals Q2 Adjusted Earnings Fall, Revenue Increases; Reaffirms Full-Year Guidance

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations
LGND

Investor's Business Daily

7 months ago

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations

LGND

Associated Press Finance

7 months ago

Ligand: Q2 Earnings Snapshot

Ligand Reports Second Quarter 2024 Financial Results
LGND

Business Wire

7 months ago

Ligand Reports Second Quarter 2024 Financial Results

LGND

MT Newswires

7 months ago

Ligand Pharmaceuticals COO Matthew Korenberg to Step Down

Hidden Gems Undiscovered Companies with Strong Fundamentals For July 2024
LGND

Simply Wall St.

7 months ago

Hidden Gems Undiscovered Companies with Strong Fundamentals For July 2024

Undiscovered Gems In The United States For July 2024
LGND

Simply Wall St.

7 months ago

Undiscovered Gems In The United States For July 2024

LGND

MT Newswires

7 months ago

RBC Initiates Ligand Pharmaceuticals at Outperform With $130 Price Target

LGND

Argus Research

7 months ago

LGND: Raising target price to $107.00

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
LGND

Business Wire

7 months ago

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

LGND

Argus Research

7 months ago

LGND: Raising target price to $104.00

LGND

Argus Research

7 months ago

LGND: Raising target price to $96.00

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m
LGND

Pharmaceutical Technology

7 months ago

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

LGND

MT Newswires

7 months ago

Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties

Ligand to buy Apeiron; Roche reports another TIGIT setback
LGND

BioPharma Dive

7 months ago

Ligand to buy Apeiron; Roche reports another TIGIT setback

Ligand to Acquire APEIRON Biologics AG for $100 Million
LGND

Business Wire

7 months ago

Ligand to Acquire APEIRON Biologics AG for $100 Million

LGND

Argus Research

8 months ago

LGND: Raising target price to $89.00

Lifecore Biomedical Announces Cooperation Agreement with 22NW
LGND

GlobeNewswire

8 months ago

Lifecore Biomedical Announces Cooperation Agreement with 22NW

LGND

MT Newswires

8 months ago

Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
LGND

Business Wire

8 months ago

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
LGND

Zacks

8 months ago

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
LGND

Zacks

8 months ago

Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?

Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
LGND

Zacks

8 months ago

Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics

The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not been profitable
LGND

Simply Wall St.

8 months ago

The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not been profitable

LGND

MT Newswires

8 months ago

Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
LGND

Business Wire

8 months ago

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
LGND

Zacks

8 months ago

Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study

Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
LGND

Zacks

8 months ago

Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment

Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
LGND

Zacks

8 months ago

Shattuck (STTK) Announces Positive Interim Data on Cancer Drug

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
LGND

Zacks

8 months ago

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro

What Makes Ligand (LGND) a New Strong Buy Stock
LGND

Zacks

8 months ago

What Makes Ligand (LGND) a New Strong Buy Stock

Why Is Ligand (LGND) Up 4% Since Last Earnings Report?
LGND

Zacks

9 months ago

Why Is Ligand (LGND) Up 4% Since Last Earnings Report?

Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect?
LGND

Zacks

9 months ago

Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect?

Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why
LGND

Zacks

9 months ago

Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why

Ligand to Participate in Upcoming Investor Conferences
LGND

Business Wire

9 months ago

Ligand to Participate in Upcoming Investor Conferences

AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
LGND

Zacks

9 months ago

AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030

Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
LGND

Zacks

9 months ago

Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies

PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
LGND

Zacks

9 months ago

PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug

BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
LGND

Zacks

9 months ago

BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why

Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control
LGND

Zacks

9 months ago

Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control

Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
LGND

Zacks

9 months ago

Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC

Ionis (IONS), Biogen Down on Ending Development of ALS Drug
LGND

Zacks

9 months ago

Ionis (IONS), Biogen Down on Ending Development of ALS Drug

Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
LGND

Zacks

9 months ago

Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus

Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
LGND

Zacks

9 months ago

Vanda (VNDA) Rises on Positive Data From Motion Sickness Study

Insider Sale: President & Chief Operating Officer Matthew Korenberg Sells Shares of Ligand ...
LGND

GuruFocus.com

9 months ago

Insider Sale: President & Chief Operating Officer Matthew Korenberg Sells Shares of Ligand ...

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
LGND

Zacks

9 months ago

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing

Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
LGND

Zacks

9 months ago

Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag

Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
LGND

Zacks

9 months ago

Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals

Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
LGND

Zacks

9 months ago

Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility

Share on Social Networks: